Skip to content
Specimen Atlas of Research Peptides81 plates · MIT
← CataloguePlate XIV of 81
XIVPlate XIVReviewed 2026-04-27

Chonluten

Bioregulatory Peptide

also known as bronchial bioregulator, respiratory peptide complex

Khavinson-school bioregulatory peptide complex targeting bronchial mucosa and respiratory epithelium. Preclinical data demonstrate modulation of proliferative activity and inflammatory pathways in monocyte/macrophage cell lines. Part of the Russian bioregulator tradition with tissue-specific organ peptide architecture. Limited Western research indexing; mechanistic evidence from in vitro models.

§ I

At a glance

Target tissue
Bronchial
Evidence tier
In vitro
Model system
THP-1
Route

Oral · Sublingual · Per Protocol

§ II

Mechanism

Edit ↗

Primary target — Bronchial epithelial cells and respiratory mucosa tissue complexes.

Pathway — Bioregulatory peptide interaction → modulation of proliferative and inflammatory pathways in monocyte/macrophage populations [avolio-2022].

Downstream effect — Regulation of proliferative activity and inflammatory mediator production in respiratory-associated immune cells [avolio-2022].

Origin — Khavinson bioregulator peptide complex derived from bronchial mucosa tissue extract methodology.

§ III

Dosage

Protocols described in the cited literature; not medical advice.

Edit ↗
ParameterValue
Typical protocol dose10–20 mg / dayRussian bioregulator tradition dosing; not standardized in Western literature.
FrequencyOnce or twice daily
RouteOral (capsule) or sublingualSublingual claimed for enhanced bioavailability; not validated.
Evidence basisIn vitro mechanistic
Duration10–30 days per cycleTraditional Khavinson protocol; cyclic administration common.
Clinical validationNone (PubMed indexed)
§ III · b

Reconstitution

A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.

Inputs
mg
mL
mcg
The calculator does pure mass-to-volume math. It does not recommend a dose. Refer to Chonluten's cited literature for protocol specifics.
Volumetric outputFig. C — reconstitution math
Volume per dose
0.100mL
10.0 units on a U-100 insulin syringe
Concentration
2500
mcg per mL
Doses per vial
20
at this dose
§ V

Adverse events

Severities follow the FDA / CTCAE convention.

Edit ↗
Documented adverse eventsmild
No published safety data in PubMed-indexed literature
Theoretical risksmild
Peptide hypersensitivity, GI intolerance (uncharacterized)
Drug interactionsmild
Unknown — no pharmacokinetic studies available
Pregnancy / lactationmoderate
No data — avoid
Absolute contraindications
  • Known hypersensitivity to peptide components
Relative contraindications
  • Pregnancy and lactation (insufficient data)
  • Active malignancy (theoretical bioregulator concern)
§ VI

Administration

Edit ↗
  1. 01
    Preparation

    Typically supplied as capsules or sublingual tablets. No reconstitution required. Store in cool, dry place away from light.

  2. 02
    Oral route

    Swallow capsule with water, 20–30 minutes before meals or as directed. Traditional Khavinson protocol emphasizes empty stomach for absorption.

  3. 03
    Sublingual route

    Place tablet under tongue, allow dissolution for 1–2 minutes. Avoid swallowing immediately. Claimed to bypass first-pass metabolism.

  4. 04
    Timing

    Morning dose preferred; may split into twice-daily if higher dose used. Consistency emphasized in bioregulator protocols.

  5. 05
    Cycle protocol

    10–30 day cycles common in Russian tradition. Rest period of 1–3 months between cycles often recommended, though no published evidence for this approach.

Appendix

Sources

21%

of 38 rendered claims carry a resolvable citation.

  1. [avolio-2022]
    Avolio 2022Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line.
    journal, 2022
Plate composed 2026-04-27 · maturity human-reviewed · schema v1 · Contributors: peptidesdb-core · 30 fields uncited — open contributions